Case Report - (2024) Volume 15, Issue 6
Background: Type 1 Diabetes Mellitus (T1DM) is an autoimmune disease leading to the destruction of pancreatic beta cells and requiring lifelong insulin therapy. Stem cell therapy is a novel treatment approach aimed at regenerating or replacing damaged beta cells.
Case presentation: We report the case of a 25-year-old female with a 10- year history of poorly controlled T1DM despite intensive insulin therapy. The patient experienced frequent hypoglycemic episodes and early signs of diabetic complications.
Intervention: The patient underwent autologous hematopoietic stem cell transplantation (HSCT). Peripheral blood stem cells were mobilized using granulocyte-colony stimulating factor (G-CSF) and collected via apheresis. After conditioning with cyclophosphamide and antithymocyte globulin, the patient received the autologous stem cell infusion.
Results: Post-transplantation, the patient showed significant improvement in glycemic control, reduced insulin requirements, and increased C-peptide levels, indicating endogenous insulin production. During the 12-month follow-up, the patient maintained improved glycemic control with minimal insulin supplementation and no severe hypoglycemic events. Early diabetic complications stabilized, and the patient reported an enhanced quality of life.
Conclusion: This case demonstrates the potential of autologous HSCT in improving clinical outcomes for T1DM patients by restoring beta cell function. Stem cell therapy offers a regenerative approach that may alter the disease course and reduce long-term complications. Further research is needed to validate these findings and establish standardized protocols for clinical application.
Type 1 Diabetes Mellitus; T1DM; Autologous stem cell therapy; Hematopoietic stem cell transplantation; HSCT; Glycemic control; Insulin production; Diabetic complications; Regenerative medicine; Stem cell transplantation; Beta cell regeneration; Exogenous insulin dependency
Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder that results in the immune-mediated destruction of insulin-producing beta cells within the pancreatic islets of Langerhans. This destruction leads to an absolute deficiency in insulin, a critical hormone for regulating blood glucose levels. Consequently, individuals with T1DM require lifelong dependence on exogenous insulin to manage their blood sugar levels and prevent complications such as ketoacidosis, retinopathy, nephropathy, and neuropathy. Despite advancements in insulin therapy and glucose monitoring, maintaining optimal glycemic control remains challenging, and patients often experience fluctuating glucose levels, which can lead to both acute and chronic complications. Stem cell therapy has emerged as a revolutionary treatment modality with the potential to regenerate or replace the damaged beta cells, thereby addressing the root cause of T1DM rather than just managing its symptoms [1,2]. This approach involves using stem cells, which have the ability to differentiate into various cell types, including insulin-producing beta cells. Autologous stem cell therapy, which uses the patient's own stem cells, has gained attention due to its lower risk of immune rejection and ethical concerns.
A 25-year-old female with a decade-long history of Type 1 Diabetes Mellitus (T1DM) presented with ongoing challenges in managing her blood glucose levels, despite rigorous insulin therapy. The patient’s diabetes was marked by frequent and severe hypoglycemic episodes, which significantly impacted her daily life and increased the risk of acute complications. Additionally, she showed early signs of diabetic retinopathy, evidenced by changes in the retina detectable upon ophthalmic examination, and neuropathy, characterized by tingling and numbness in her extremities. These complications indicated an advancing progression of her diabetes, despite adhering to a strict insulin regimen and lifestyle modifications. Her inability to maintain stable blood glucose levels and the onset of diabetic complications underscored the limitations of conventional treatments and highlighted the urgent need for alternative therapeutic strategies [3-5]. This scenario set the stage for considering innovative interventions such as stem cell therapy, aimed at addressing the root cause of beta cell destruction and potentially restoring normal insulin production. The patient's case reflects the complex challenges faced by individuals with long-standing T1DM and the need for novel approaches to improve disease management and quality of life.
Intervention
After comprehensive evaluation, the patient was deemed eligible for autologous hematopoietic stem cell transplantation (HSCT). Peripheral blood stem cells were mobilized using granulocyte-colony stimulating factor (G-CSF) and collected via apheresis. Following a conditioning regimen with cyclophosphamide and antithymocyte globulin, the patient received the autologous stem cell infusion [6].
Outcome
Post-transplantation, the patient exhibited significant improvement in glycemic control. Insulin requirements reduced progressively, and C-peptide levels increased, indicating endogenous insulin production. Over a 12-month follow-up period, the patient maintained improved glycemic control with minimal insulin supplementation and reported no severe hypoglycemic events. Retinopathy and neuropathy progression stabilized, and overall quality of life improved [7].
This case highlights the potential of autologous hematopoietic stem cell transplantation (HSCT) in restoring beta cell function and improving clinical outcomes in patients with Type 1 Diabetes Mellitus (T1DM). T1DM is characterized by an autoimmune-mediated destruction of insulin-producing beta cells in the pancreas, leading to an absolute deficiency of insulin and lifelong dependence on exogenous insulin. Current treatments focus on insulin replacement and managing complications, but they do not address the underlying autoimmune process or promote beta cell regeneration [8].
Autologous HSCT offers a regenerative approach by using the patient's own stem cells to potentially regenerate or replace damaged beta cells. In this case, the patient experienced significant improvements in glycemic control, with reduced insulin requirements and increased endogenous insulin production as evidenced by elevated C-peptide levels. This suggests that stem cell therapy may help restore beta cell function, offering a more physiological regulation of blood glucose levels. Additionally, the patient reported stabilization of early diabetic complications and an overall improved quality of life [9].
Stem cell therapy could fundamentally alter the course of T1DM by targeting the root cause of the disease and reducing the burden of long-term complications such as retinopathy, neuropathy, and cardiovascular issues. However, the success observed in this single case needs to be validated through further studies involving larger cohorts and extended follow-up periods. These studies are necessary to confirm the long-term efficacy and safety of stem cell therapy, identify optimal patient selection criteria, and establish standardized treatment protocols. Addressing these issues will be crucial for translating the potential benefits of stem cell therapy into routine clinical practice for T1DM patients [10].
Autologous stem cell therapy represents a promising therapeutic option for patients with Type 1 Diabetes Mellitus (T1DM), potentially revolutionizing disease management and significantly enhancing quality of life. By utilizing the patient's own stem cells, this approach aims to regenerate damaged pancreatic beta cells, restoring endogenous insulin production and reducing dependency on exogenous insulin. This case exemplifies the potential benefits, including improved glycemic control, reduced insulin requirements, and stabilization of early diabetic complications. The success observed in this case underscores the transformative potential of stem cell-based therapies in altering the disease course of T1DM.
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Citation: Sokolayam Ibrahim. Stem Cell Therapy for Type 1 Diabetes Mellitus. J Diabetes Metab, 2024, 15(6): 1135.
Received: 01-Jun-2024, Manuscript No. jdm-24-33091; Editor assigned: 03-Jun-2024, Pre QC No. jdm-24-33091(PQ); Reviewed: 17-Jun-2024, QC No. jdm-24-33091; Revised: 21-Jun-2024, Manuscript No. jdm-24-33091(R); Published: 28-Jun-2024
Copyright: © 2024 Sokolayam I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
